🔎 Trials Near Me

Utama › Penyakit Paru Interstisial › Texas › Houston

Kajian klinikal Penyakit Paru Interstisial di Houston, TX

12 kajian untuk Penyakit Paru Interstisial sedang mencari peserta di lokasi dalam dan sekitar Houston (dalam lingkungan kira-kira 30 batu). Buka kajian untuk melihat siapa yang layak menyertai dan cara menghubungi pasukan kajian.

Teks kajian rasmi (Bahasa Inggeris)

Mengambil peserta untuk kajian di sini? Paparkan di bahagian atas halaman ini — $99 selama 30 hari →

A Study to Test Whether Nerandomilast Can Help Slow Down Changes in the Lung in People With a Family History of Pulmonary Fibrosis

Mengambil pesertaFasa 3
  • Baylor College of Medicine, Houston
Umur 40 ke atas · Semua jantina · Dikemas kini 30 Sep 2026 · NCT07201922

A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease

Mengambil pesertaFasa 3
  • GSK Investigational Site, Houston
Umur 18 ke atas · Semua jantina · Dikemas kini 8 Sep 2026 · NCT06572384

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

Mengambil pesertaFasa 2
  • Baylor College of Medicine, Houston
Umur 40 ke atas · Semua jantina · Dikemas kini 4 Sep 2026 · NCT06968845

Multi-site Study of the Clinical Impact of an AI-assisted Approach to Referring Patients With Interstitial Lung Disease for Diagnostic Evaluation of Pulmonary Hypertension

Mengambil peserta
  • Baylor College of Medicine, Houston
  • Houston Methodist Hospital, Houston
Umur 18 ke atas · Semua jantina · Dikemas kini 2 Sep 2026 · NCT06911632

A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD

Mengambil pesertaFasa 2
  • Clinical Research Site, Houston
Umur 18 hingga 85 · Semua jantina · Dikemas kini 2 Sep 2026 · NCT07333183

DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)

Mengambil pesertaKajian pemerhatian
  • Houston Methodist, Houston
  • University of Texas Health Science Center at Houston, Houston
Umur 18 ke atas · Semua jantina · Dikemas kini 26 Ogo 2026 · NCT06388421

Platform Clinical Study for Conquering Scleroderma

Mengambil pesertaFasa 2
  • University of Texas Houston - Division of Rheumatology and Clinical Immunogenetics, Houston
Umur 18 ke atas · Semua jantina · Dikemas kini 18 Ogo 2026 · NCT06195072

Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease Prospective Outcomes Registry

Mengambil pesertaKajian pemerhatian
  • Baylor College of Medicine, Houston
  • Houston Methodist Lung Center, Houston
  • The University of Texas Health Science Center At Houston, Houston
Umur 21 ke atas · Semua jantina · Dikemas kini 12 Ogo 2026 · NCT01915511

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

Mengambil pesertaFasa 2
  • Houston Methodist Hospital, Houston
Umur 18 hingga 80 · Semua jantina · Dikemas kini 10 Ogo 2026 · NCT07175038

Study of the Efficacy and Safety of Inhaled Treprostinil in Subjects With Progressive Pulmonary Fibrosis (TETON-PPF)

Mengambil pesertaFasa 3
  • Houston Methodist Outpatient Center, Houston
  • The University of Texas Health Science Center at Houston, McGovern Medical School, Houston
Umur 18 ke atas · Semua jantina · Dikemas kini 13 Jul 2026 · NCT05943535

TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients

Mengambil pesertaKajian pemerhatian
  • Baylor College of Medicine/Texas Children'S Hospital, Houston
Sehingga umur 24 · Semua jantina · Dikemas kini 22 Jun 2026 · NCT04098445

Study to Evaluate the Efficacy, Safety, and Tolerability of Efzofitimod in Patients With Systemic Sclerosis (SSc)-Related Interstitial Lung Disease (ILD) (SSc-ILD)

Mengambil pesertaFasa 2
  • aTyr Investigative Site, Houston
Umur 18 ke atas · Semua jantina · Dikemas kini 7 Mei 2025 · NCT05892614

Kajian Penyakit Paru Interstisial di bandar lain

Kajian lain di Houston

Daripada ClinicalTrials.gov, data diperoleh pada 5 Okt 2026. Setiap kajian menetapkan kriteria kelayakannya sendiri; pasukan kajian menentukan siapa yang layak menyertai.